Loading
Dianthus Therapeutics, Inc. /DE/ Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Fairmount Funds Management LLC, was filed 03 Oct 2023.
Insider Decl.
214
Thresholds
n/a
Buy Volume
€10M
10 ops. · all time
Sell Volume
€66M
102 ops. · all time
Who traded when
BuySaleSavitz Ryan14 sales
Garcia Marino12 sales
Edward Carr10 sales
Simrat Randhawa8 sales
Simon Read7 sales
Adam M. Veness5 sales
+2 other insiders
Since the insiders bought
- +122.0%Entry US$12.37 · Close at T+365 US$27.46
- +102.5%Entry US$13.18 · Close at T+365 US$26.69
- +24.0%Entry US$127.52 · Close at T+365 US$158.08
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Dianthus Therapeutics, Inc. /DE/ Strong Buy (bullish), based on 15 analysts. Average price target: US$140.80.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$78.10
Analyst consensus
15 analystsStrong buy
US$122.00Target US$140.80(+80%)US$200.00
Income statement
RevenueUS$2M
EBITDA-US$177.5M-8718% margin
Net income-US$162.3M-7973.3% margin
Valuation
PER (forward)-16.9x
P/Book3.7x
Beta0.18
Balance sheet & cash
Market capUS$4.3B
Total debtUS$1.4M
Free Cash Flow-US$129.3M
Debt / Equity0%
Profitability & ownership
ROE-26.1%
ROA-17.7%
% insiders0.1%
% institutions128.7%
Last declaration on 18 September 2026
Declarations214 total
20,000 shares@ US$17.880.0086% mcap13.4% of flowCommon StockSEC:0001273351-26-000006:0
7,928 shares@ US$100.430.019% mcap29.8% of flowCommon StockSEC:0001273351-26-000006:1
6,771 shares@ US$101.370.016% mcap25.7% of flowCommon StockSEC:0001273351-26-000006:2
3,501 shares@ US$102.390.0086% mcap13.4% of flowCommon StockSEC:0001273351-26-000006:3
1,100 shares@ US$103.200.0027% mcap4.2% of flowCommon StockSEC:0001273351-26-000006:4
700 shares@ US$104.390.0018% mcap2.7% of flowCommon StockSEC:0001273351-26-000006:5
20,000 shares@ US$102.490.049% mcap100.0% of flowCommonSEC144:0001950047-26-009619
7,500 shares@ US$17.880.0026% mcap3.6% of flowCommon StockSEC:0001992260-26-000009:0
6,249 shares@ US$21.770.0026% mcap3.6% of flowCommon StockSEC:0001992260-26-000009:1
9,375 shares@ US$22.070.0040% mcap5.5% of flowCommon StockSEC:0001992260-26-000009:2
2,600 shares@ US$105.190.0052% mcap7.3% of flowCommon StockSEC:0001992260-26-000009:3
7,215 shares@ US$106.250.015% mcap20.5% of flowCommon StockSEC:0001992260-26-000009:4
13,309 shares@ US$106.740.027% mcap37.9% of flowCommon StockSEC:0001992260-26-000009:5
2,778 shares@ US$18.360.0010% mcap3.8% of flowCommon StockSEC:0001688199-26-000006:0
2,778 shares@ US$117.550.0063% mcap24.0% of flowCommon StockSEC:0001688199-26-000006:1
15,000 shares@ US$18.170.0053% mcap9.6% of flowCommon StockSEC:0001778623-26-000009:0
70 shares@ US$107.110.0001% mcap0.6% of flowCommon StockSEC:0001688199-26-000004:1
737 shares@ US$108.170.0015% mcap5.9% of flowCommon StockSEC:0001688199-26-000004:2
831 shares@ US$108.950.0017% mcap6.7% of flowCommon StockSEC:0001688199-26-000004:3
272 shares@ US$109.960.0006% mcap2.2% of flowCommon StockSEC:0001688199-26-000004:4
470 shares@ US$111.050.0010% mcap3.8% of flowCommon StockSEC:0001688199-26-000004:5
397 shares@ US$111.770.0009% mcap3.3% of flowCommon StockSEC:0001688199-26-000004:6
3,833 shares@ US$17.880.0013% mcap2.4% of flowCommon StockSEC:0001778623-26-000007:0
3,217 shares@ US$110.610.0069% mcap12.6% of flowCommon StockSEC:0001778623-26-000007:1
616 shares@ US$111.180.0013% mcap2.4% of flowCommon StockSEC:0001778623-26-000007:2
25 of 214 declarations
About Dianthus Therapeutics, Inc. /DE/
Marino Garcia, filed as CEO and President of Dianthus Therapeutics, Inc. /DE/ (Health Care), sold EUR 9,750,922 on August 7, 2026 and EUR 4,639,402 on March 12, 2026; Ryan Savitz (EVP, CFO & CBO) EUR 4,334,828 on March 31, 2026. The record's 103 sales total EUR 66,697,882, with a median of EUR 142,753, against 10 purchases worth EUR 10,345,483 (median EUR 126,415), or 9% of open-market trades.
The largest purchase is by director Bruce Booth: EUR 8,891,100 on June 29, 2020. Fairmount Funds Management LLC, filed as a director, bought EUR 373,244 on September 26, 2023 and EUR 370,715 on September 19, 2023. From September 12 to September 29, 2023, 2 filers bought EUR 1,364,661 worth. Across the full history, 6 purchase filings are classed as clustered.
Read moreShow less
Of 213 filings from 40 filers, 45 are option exercises, 36 are of another kind and 19 are grants. Simrat Randhawa (EVP, Head of R&D) files 22, of which 2 purchases and 8 sales, Ryan Savitz 20 and Marino Garcia 17. The year 2026 concentrates 96 filings. The last twelve months hold 107, of which 62 sales and no purchase. Insiders hold 0.1% of the capital, valued at USD 4.3 billion. Publication comes 1 day after the trade at the median.
